Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Hansa Biopharma Appoints New CEO | Contract Pharma

What are you searching for?

Sign in
Promotions & Moves

Hansa Biopharma Appoints New CEO

Renée Aguiar-Lucander joins the company as Søren Tulstrup steps down as CEO.

By: Rachel Klemovitch

Assistant Editor

Hansa Biopharma AB appointed Renée Aguiar-Lucander as Chief Executive Officer (CEO), effective immediately. Søren Tulstrup will be stepping down from his position as CEO by mutual agreement after seven years with the company.

“On behalf of the Board of Directors, I would like to extend our gratitude to Søren for his leadership and significant contribution to the company during his tenure,” said Peter Nicklin, Chairman of the Board, Hansa Biopharma. “With the appointment of Renée as CEO, Hansa is entering a new phase of growth and development. Renée brings extensive experience in both the biopharmaceutical and financial sectors, and her proven leadership will be instrumental in advancing the Company’s strategic positioning.”

Aguiar-Lucander served for seven years as CEO of Calliditas Therapeutics AB, where she successfully led the company through a dual listing on NASDAQ in Sweden and the U.S. 

During her tenure, the company successfully launched and commercialized the first ever approved drug for immunoglobulin A (IgA) nephropathy in the U.S. Before that, Aguiar-Lucander had a long and successful career in the healthcare investment sector, holding senior roles in funds such as Omega Funds and 3i Group.

Aguiar-Lucander, commented, I “hope to bring relevant perspectives from my previous roles, both with regards to capital raising and management, as well as insights regarding regulatory, commercial preparation, and launch dynamics. I look forward to working with the team and Board to ensure Hansa’s future success.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters